3 great minds agree: AI is changing everything

Three distinguished thinkers who think a lot on the future are asking some big questions about AI.

How will the technology’s evolution affect human perception, cognition and interaction? Will AI lead to an as-yet-unimaginable expansion of familiar reality? What will be its impact on our culture and, in the end, our history?

It’s not like other great minds haven’t been mulling the same questions, and for some time now.

But when 96-year-old Henry Kissinger has something to say, people listen. Rightly so.  

And the attention is likely to be all the more rapt when his co-authors are people like Eric Schmidt, the former CEO and chairman of Alphabet, and Daniel Huttenlocher, dean of the MIT Schwarzman College of Computing. 

Taking to pages of The Atlantic, the trio note that the phenomenon of a machine that can match or exceed humans in cognitive processing—in the process both predicting and shaping things to come—is unique in history.

Importantly, they underscore, all questions now being asked about AI “must be undertaken according to three time horizons: what we already know, what we are sure to discover in the near future, and what we are likely to discover when AI becomes widespread.”

It’s a sprawling yet succinct think piece that deserves a read by all working in, with or around AI.

Check it out:

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.